Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 361 to 372 of 372 entries
Sorted by: Best Match Show Resources per page
Inheritance of pheromone profiles from aged .

microPublication biology

Brown SG, Brenman-Suttner DB, McInnes AG, Lew K, Moehring AJ, Bauer JH, Simon AF.
PMID: 34723148
MicroPubl Biol. 2021 Oct 11;2021. doi: 10.17912/micropub.biology.000459. eCollection 2021.

Through aging,

Cite
Brown SG, Brenman-Suttner DB, McInnes AG, et al. Inheritance of pheromone profiles from aged . MicroPubl Biol. 2021;2021doi: 10.17912/micropub.biology.000459.
Brown, S. G., Brenman-Suttner, D. B., McInnes, A. G., Lew, K., Moehring, A. J., Bauer, J. H., & Simon, A. F. (2021). Inheritance of pheromone profiles from aged . microPublication biology, 2021. https://doi.org/10.17912/micropub.biology.000459
Brown, Samuel G, et al. "Inheritance of pheromone profiles from aged ." microPublication biology vol. 2021 (2021). doi: https://doi.org/10.17912/micropub.biology.000459
Brown SG, Brenman-Suttner DB, McInnes AG, Lew K, Moehring AJ, Bauer JH, Simon AF. Inheritance of pheromone profiles from aged . MicroPubl Biol. 2021 Oct 11;2021. doi: 10.17912/micropub.biology.000459. eCollection 2021. PMID: 34723148; PMCID: PMC8553430.
Copy Download .nbib Format: NLM
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.

Annals of the rheumatic diseases

Machado PM, Lawson-Tovey S, Strangfeld A, Mateus EF, Hyrich KL, Gossec L, Carmona L, Rodrigues A, Raffeiner B, Duarte C, Hachulla E, Veillard E, Strakova E, Burmester GR, Yardımcı GK, Gomez-Puerta JA, Zepa J, Kearsley-Fleet L, Trefond L, Cunha M, Mosca M, Cornalba M, Soubrier M, Roux N, Brocq O, Durez P, Conway R, Goulenok T, Bijlsma JW, McInnes IB, Mariette X.
PMID: 34972811
Ann Rheum Dis. 2021 Dec 31; doi: 10.1136/annrheumdis-2021-221490. Epub 2021 Dec 31.

OBJECTIVES: To describe the safety of vaccines against SARS-CoV-2 in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD).METHODS: Physician-reported registry of I-RMD and non-inflammatory RMD (NI-RMDs) patients vaccinated against SARS-CoV-2. From 5 February 2021 to 27 July 2021, we...

Cite
Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2021-221490.
Machado, P. M., Lawson-Tovey, S., Strangfeld, A., Mateus, E. F., Hyrich, K. L., Gossec, L., Carmona, L., Rodrigues, A., Raffeiner, B., Duarte, C., Hachulla, E., Veillard, E., Strakova, E., Burmester, G. R., Yardımcı, G. K., Gomez-Puerta, J. A., Zepa, J., Kearsley-Fleet, L., Trefond, L., Cunha, M., Mosca, M., Cornalba, M., Soubrier, M., Roux, N., Brocq, O., Durez, P., Conway, R., Goulenok, T., Bijlsma, J. W., McInnes, I. B., & Mariette, X. (2021). Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2021-221490
Machado, Pedro M, et al. "Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2021-221490
Machado PM, Lawson-Tovey S, Strangfeld A, Mateus EF, Hyrich KL, Gossec L, Carmona L, Rodrigues A, Raffeiner B, Duarte C, Hachulla E, Veillard E, Strakova E, Burmester GR, Yardımcı GK, Gomez-Puerta JA, Zepa J, Kearsley-Fleet L, Trefond L, Cunha M, Mosca M, Cornalba M, Soubrier M, Roux N, Brocq O, Durez P, Conway R, Goulenok T, Bijlsma JW, McInnes IB, Mariette X. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2021 Dec 31; doi: 10.1136/annrheumdis-2021-221490. Epub 2021 Dec 31. PMID: 34972811.
Copy Download .nbib Format: NLM
Radiative balance and temperature of differently pigmented cotton canopies.

International journal of biometeorology

Carvalho HDR, McInnes KJ, Heilman JL, Maeda MM.
PMID: 34988681
Int J Biometeorol. 2022 Jan 06; doi: 10.1007/s00484-021-02221-x. Epub 2022 Jan 06.

Pigments are known to modify the spectral properties of foliage, which in turn affect the amount of radiant energy stored by the plant canopy. Studies have shown that red pigments (anthocyanin) increase leaf absorptivity of solar radiation, but little...

Cite
Carvalho HDR, McInnes KJ, Heilman JL, et al. Radiative balance and temperature of differently pigmented cotton canopies. Int J Biometeorol. 2022;doi: 10.1007/s00484-021-02221-x.
Carvalho, H. D. R., McInnes, K. J., Heilman, J. L., & Maeda, M. M. (2022). Radiative balance and temperature of differently pigmented cotton canopies. International journal of biometeorology, . https://doi.org/10.1007/s00484-021-02221-x
Carvalho, Henrique D R, et al. "Radiative balance and temperature of differently pigmented cotton canopies." International journal of biometeorology vol. (2022). doi: https://doi.org/10.1007/s00484-021-02221-x
Carvalho HDR, McInnes KJ, Heilman JL, Maeda MM. Radiative balance and temperature of differently pigmented cotton canopies. Int J Biometeorol. 2022 Jan 06; doi: 10.1007/s00484-021-02221-x. Epub 2022 Jan 06. PMID: 34988681.
Copy Download .nbib Format: NLM
Atomically Dispersed Copper Sites in a Metal-Organic Framework for Reduction of Nitrogen Dioxide.

Journal of the American Chemical Society

Ma Y, Han X, Xu S, Wang Z, Li W, da Silva I, Chansai S, Lee D, Zou Y, Nikiel M, Manuel P, Sheveleva AM, Tuna F, McInnes EJL, Cheng Y, Rudić S, Ramirez-Cuesta AJ, Haigh SJ, Hardacre C, Schröder M, Yang S.
PMID: 34279096
J Am Chem Soc. 2021 Jul 28;143(29):10977-10985. doi: 10.1021/jacs.1c03036. Epub 2021 Jul 19.

Metal-organic framework (MOF) materials provide an excellent platform to fabricate single-atom catalysts due to their structural diversity, intrinsic porosity, and designable functionality. However, the unambiguous identification of atomically dispersed metal sites and the elucidation of their role in catalysis...

Cite
Ma Y, Han X, Xu S, et al. Atomically Dispersed Copper Sites in a Metal-Organic Framework for Reduction of Nitrogen Dioxide. J Am Chem Soc. 2021;143(29):10977-10985doi: 10.1021/jacs.1c03036.
Ma, Y., Han, X., Xu, S., Wang, Z., Li, W., da Silva, I., Chansai, S., Lee, D., Zou, Y., Nikiel, M., Manuel, P., Sheveleva, A. M., Tuna, F., McInnes, E. J. L., Cheng, Y., Rudić, S., Ramirez-Cuesta, A. J., Haigh, S. J., Hardacre, C., Schröder, M., & Yang, S. (2021). Atomically Dispersed Copper Sites in a Metal-Organic Framework for Reduction of Nitrogen Dioxide. Journal of the American Chemical Society, 143(29), 10977-10985. https://doi.org/10.1021/jacs.1c03036
Ma, Yujie, et al. "Atomically Dispersed Copper Sites in a Metal-Organic Framework for Reduction of Nitrogen Dioxide." Journal of the American Chemical Society vol. 143,29 (2021): 10977-10985. doi: https://doi.org/10.1021/jacs.1c03036
Ma Y, Han X, Xu S, Wang Z, Li W, da Silva I, Chansai S, Lee D, Zou Y, Nikiel M, Manuel P, Sheveleva AM, Tuna F, McInnes EJL, Cheng Y, Rudić S, Ramirez-Cuesta AJ, Haigh SJ, Hardacre C, Schröder M, Yang S. Atomically Dispersed Copper Sites in a Metal-Organic Framework for Reduction of Nitrogen Dioxide. J Am Chem Soc. 2021 Jul 28;143(29):10977-10985. doi: 10.1021/jacs.1c03036. Epub 2021 Jul 19. PMID: 34279096; PMCID: PMC8323097.
Copy Download .nbib Format: NLM
Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety.

Pharmacology & therapeutics

Kolbinger F, Di Padova F, Deodhar A, Hawkes JE, Huppertz C, Kuiper T, McInnes IB, Ritchlin CT, Rosmarin D, Schett G, Carballido JM, Häusermann P, Calonder C, Vogel B, Rondeau JM, Bruin G.
PMID: 34171337
Pharmacol Ther. 2022 Jan;229:107925. doi: 10.1016/j.pharmthera.2021.107925. Epub 2021 Jun 23.

Psoriasis, psoriatic arthritis, and axial spondyloarthritis are systemic inflammatory diseases, each commonly manifesting as a spectrum of symptoms, complications, and comorbidities that arise differently in individual patients. Drugs targeting inflammatory cytokines common to the pathogenesis of each of these...

Cite
Kolbinger F, Di Padova F, Deodhar A, et al. Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety. Pharmacol Ther. 2021;229:107925doi: 10.1016/j.pharmthera.2021.107925.
Kolbinger, F., Di Padova, F., Deodhar, A., Hawkes, J. E., Huppertz, C., Kuiper, T., McInnes, I. B., Ritchlin, C. T., Rosmarin, D., Schett, G., Carballido, J. M., Häusermann, P., Calonder, C., Vogel, B., Rondeau, J. M., & Bruin, G. (2022). Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety. Pharmacology & therapeutics, 229107925. https://doi.org/10.1016/j.pharmthera.2021.107925
Kolbinger, Frank, et al. "Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety." Pharmacology & therapeutics vol. 229 (2022): 107925. doi: https://doi.org/10.1016/j.pharmthera.2021.107925
Kolbinger F, Di Padova F, Deodhar A, Hawkes JE, Huppertz C, Kuiper T, McInnes IB, Ritchlin CT, Rosmarin D, Schett G, Carballido JM, Häusermann P, Calonder C, Vogel B, Rondeau JM, Bruin G. Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety. Pharmacol Ther. 2022 Jan;229:107925. doi: 10.1016/j.pharmthera.2021.107925. Epub 2021 Jun 23. PMID: 34171337.
Copy Download .nbib Format: NLM
Novel self-amplificatory loop between T cells and tenocytes as a driver of chronicity in tendon disease.

Annals of the rheumatic diseases

Garcia-Melchor E, Cafaro G, MacDonald L, Crowe LAN, Sood S, McLean M, Fazzi UG, McInnes IB, Akbar M, Millar NL.
PMID: 33692018
Ann Rheum Dis. 2021 Mar 10; doi: 10.1136/annrheumdis-2020-219335. Epub 2021 Mar 10.

OBJECTIVES: Increasing evidence suggests that inflammatory mechanisms play a key role in chronic tendon disease. After observing T cell signatures in human tendinopathy, we explored the interaction between T cells and tendon stromal cells or tenocytes to define their...

Cite
Garcia-Melchor E, Cafaro G, MacDonald L, et al. Novel self-amplificatory loop between T cells and tenocytes as a driver of chronicity in tendon disease. Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2020-219335.
Garcia-Melchor, E., Cafaro, G., MacDonald, L., Crowe, L. A. N., Sood, S., McLean, M., Fazzi, U. G., McInnes, I. B., Akbar, M., & Millar, N. L. (2021). Novel self-amplificatory loop between T cells and tenocytes as a driver of chronicity in tendon disease. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-219335
Garcia-Melchor, Emma, et al. "Novel self-amplificatory loop between T cells and tenocytes as a driver of chronicity in tendon disease." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2020-219335
Garcia-Melchor E, Cafaro G, MacDonald L, Crowe LAN, Sood S, McLean M, Fazzi UG, McInnes IB, Akbar M, Millar NL. Novel self-amplificatory loop between T cells and tenocytes as a driver of chronicity in tendon disease. Ann Rheum Dis. 2021 Mar 10; doi: 10.1136/annrheumdis-2020-219335. Epub 2021 Mar 10. PMID: 33692018; PMCID: PMC8292554.
Copy Download .nbib Format: NLM
Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial.

The Lancet. Rheumatology

Pratt AG, Siebert S, Cole M, Stocken DD, Yap C, Kelly S, Shaikh M, Cranston A, Morton M, Walker J, Frame S, Ng WF, Buckley CD, McInnes IB, Filer A, Isaacs JD.
PMID: 33928262
Lancet Rheumatol. 2021 Mar 09;3(5):e337-e346. doi: 10.1016/S2665-9913(21)00061-8. eCollection 2021 May.

BACKGROUND: Current rheumatoid arthritis therapies target immune inflammation and are subject to ceiling effects. Seliciclib is an orally available cyclin-dependent kinase inhibitor that suppresses proliferation of synovial fibroblasts-cells not yet targeted in rheumatoid arthritis. Part 1 of this phase...

Cite
Pratt AG, Siebert S, Cole M, et al. Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial. Lancet Rheumatol. 2021;3(5):e337-e346doi: 10.1016/S2665-9913(21)00061-8.
Pratt, A. G., Siebert, S., Cole, M., Stocken, D. D., Yap, C., Kelly, S., Shaikh, M., Cranston, A., Morton, M., Walker, J., Frame, S., Ng, W. F., Buckley, C. D., McInnes, I. B., Filer, A., & Isaacs, J. D. (2021). Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial. The Lancet. Rheumatology, 3(5), e337-e346. https://doi.org/10.1016/S2665-9913(21)00061-8
Pratt, Arthur G, et al. "Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial." The Lancet. Rheumatology vol. 3,5 (2021): e337-e346. doi: https://doi.org/10.1016/S2665-9913(21)00061-8
Pratt AG, Siebert S, Cole M, Stocken DD, Yap C, Kelly S, Shaikh M, Cranston A, Morton M, Walker J, Frame S, Ng WF, Buckley CD, McInnes IB, Filer A, Isaacs JD. Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial. Lancet Rheumatol. 2021 Mar 09;3(5):e337-e346. doi: 10.1016/S2665-9913(21)00061-8. eCollection 2021 May. PMID: 33928262; PMCID: PMC8062952.
Copy Download .nbib Format: NLM
Long-term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis.

Arthritis & rheumatology (Hoboken, N.J.)

McInnes IB, Rahman P, Gottlieb AB, Hsia EC, Kollmeier AP, Xu XL, Jiang Y, Sheng S, Shawi M, Chakravarty SD, van der Heijde D, Mease PJ.
PMID: 34719872
Arthritis Rheumatol. 2021 Nov 01; doi: 10.1002/art.42010. Epub 2021 Nov 01.

OBJECTIVE: Assess long-term efficacy and safety of guselkumab, an IL-23p19-subunit inhibitor, in patients with active psoriatic arthritis (PsA) from the Phase-3 DISCOVER-2 trial.METHODS: In DISCOVER-2, patients with active PsA (≥5 swollen and ≥5 tender joints; CRP ≥0.6 mg/dL) despite...

Cite
McInnes IB, Rahman P, Gottlieb AB, et al. Long-term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis. Arthritis Rheumatol. 2021;doi: 10.1002/art.42010.
McInnes, I. B., Rahman, P., Gottlieb, A. B., Hsia, E. C., Kollmeier, A. P., Xu, X. L., Jiang, Y., Sheng, S., Shawi, M., Chakravarty, S. D., van der Heijde, D., & Mease, P. J. (2021). Long-term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.), . https://doi.org/10.1002/art.42010
McInnes, Iain B, et al. "Long-term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis." Arthritis & rheumatology (Hoboken, N.J.) vol. (2021). doi: https://doi.org/10.1002/art.42010
McInnes IB, Rahman P, Gottlieb AB, Hsia EC, Kollmeier AP, Xu XL, Jiang Y, Sheng S, Shawi M, Chakravarty SD, van der Heijde D, Mease PJ. Long-term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis. Arthritis Rheumatol. 2021 Nov 01; doi: 10.1002/art.42010. Epub 2021 Nov 01. PMID: 34719872.
Copy Download .nbib Format: NLM
Apremilast Inhibits Inflammatory Osteoclastogenesis.

Rheumatology (Oxford, England)

Degboé Y, Sunzini F, Sood S, Bozec A, Sokolova MV, Zekovic A, McInnes IB, Schett G, Goodyear CS.
PMID: 33788924
Rheumatology (Oxford). 2021 Mar 31; doi: 10.1093/rheumatology/keab315. Epub 2021 Mar 31.

BACKGROUND: Psoriatic arthritis (PsA) is associated with bone erosion and inflammation-induced bone loss, which are mediated by osteoclasts and modulated by inflammatory cytokines. Apremilast (a selective phosphodiesterase 4 inhibitor) is efficacious in PsA and acts by inhibiting cytokine production....

Cite
Degboé Y, Sunzini F, Sood S, et al. Apremilast Inhibits Inflammatory Osteoclastogenesis. Rheumatology (Oxford). 2021;doi: 10.1093/rheumatology/keab315.
Degboé, Y., Sunzini, F., Sood, S., Bozec, A., Sokolova, M. V., Zekovic, A., McInnes, I. B., Schett, G., & Goodyear, C. S. (2021). Apremilast Inhibits Inflammatory Osteoclastogenesis. Rheumatology (Oxford, England), . https://doi.org/10.1093/rheumatology/keab315
Degboé, Yannick, et al. "Apremilast Inhibits Inflammatory Osteoclastogenesis." Rheumatology (Oxford, England) vol. (2021). doi: https://doi.org/10.1093/rheumatology/keab315
Degboé Y, Sunzini F, Sood S, Bozec A, Sokolova MV, Zekovic A, McInnes IB, Schett G, Goodyear CS. Apremilast Inhibits Inflammatory Osteoclastogenesis. Rheumatology (Oxford). 2021 Mar 31; doi: 10.1093/rheumatology/keab315. Epub 2021 Mar 31. PMID: 33788924.
Copy Download .nbib Format: NLM
Immune-mediated inflammatory disease therapeutics: past, present and future.

Nature reviews. Immunology

McInnes IB, Gravallese EM.
PMID: 34518662
Nat Rev Immunol. 2021 Oct;21(10):680-686. doi: 10.1038/s41577-021-00603-1. Epub 2021 Sep 13.

Immune-mediated inflammatory diseases are common and clinically diverse. Although they are currently incurable, the therapeutic armamentarium for immune-mediated inflammatory diseases has been transformed in the past two decades. We have moved from the wide application of broad-spectrum immune modulators...

Cite
McInnes IB, Gravallese EM. Immune-mediated inflammatory disease therapeutics: past, present and future. Nat Rev Immunol. 2021;21(10):680-686doi: 10.1038/s41577-021-00603-1.
McInnes, I. B., & Gravallese, E. M. (2021). Immune-mediated inflammatory disease therapeutics: past, present and future. Nature reviews. Immunology, 21(10), 680-686. https://doi.org/10.1038/s41577-021-00603-1
McInnes, Iain B, and Gravallese, Ellen M. "Immune-mediated inflammatory disease therapeutics: past, present and future." Nature reviews. Immunology vol. 21,10 (2021): 680-686. doi: https://doi.org/10.1038/s41577-021-00603-1
McInnes IB, Gravallese EM. Immune-mediated inflammatory disease therapeutics: past, present and future. Nat Rev Immunol. 2021 Oct;21(10):680-686. doi: 10.1038/s41577-021-00603-1. Epub 2021 Sep 13. PMID: 34518662; PMCID: PMC8436867.
Copy Download .nbib Format: NLM
IL-23 orchestrating immune cell activation in arthritis.

Rheumatology (Oxford, England)

Najm A, McInnes IB.
PMID: 34668017
Rheumatology (Oxford). 2021 Oct 19;60:iv4-iv15. doi: 10.1093/rheumatology/keab266.

IL-23 is a cytokine member of the IL-12 superfamily. These heterodimeric cytokines offer broad immune regulatory activity with potential effector function in inflammatory arthritis. IL-23 is a pro-inflammatory cytokine secreted by dendritic cells and macrophages. It plays a key...

Cite
Najm A, McInnes IB. IL-23 orchestrating immune cell activation in arthritis. Rheumatology (Oxford). 2021;60:iv4-iv15doi: 10.1093/rheumatology/keab266.
Najm, A., & McInnes, I. B. (2021). IL-23 orchestrating immune cell activation in arthritis. Rheumatology (Oxford, England), 60iv4-iv15. https://doi.org/10.1093/rheumatology/keab266
Najm, Aurélie, and McInnes, Iain B. "IL-23 orchestrating immune cell activation in arthritis." Rheumatology (Oxford, England) vol. 60 (2021): iv4-iv15. doi: https://doi.org/10.1093/rheumatology/keab266
Najm A, McInnes IB. IL-23 orchestrating immune cell activation in arthritis. Rheumatology (Oxford). 2021 Oct 19;60:iv4-iv15. doi: 10.1093/rheumatology/keab266. PMID: 34668017; PMCID: PMC8527242.
Copy Download .nbib Format: NLM
Pseudo-data generation for the extraction of Problems, Treatments and Tests.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science

Smith J, French E, Cramer W, Uzuner Ӧ, McInnes BT.
PMID: 34457173
AMIA Jt Summits Transl Sci Proc. 2021 May 17;2021:575-584. eCollection 2021.

One of the primary challenges for clinical Named Entity Recognition (NER) is the availability of annotated training data. Technical and legal hurdles prevent the creation and release of corpora related to electronic health records (EHRs). In this work, we...

Cite
Smith J, French E, Cramer W, et al. Pseudo-data generation for the extraction of Problems, Treatments and Tests. AMIA Jt Summits Transl Sci Proc. 2021;2021:575-584
Smith, J., French, E., Cramer, W., Uzuner, �. �., & McInnes, B. T. (2021). Pseudo-data generation for the extraction of Problems, Treatments and Tests. AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science, 2021575-584.
Smith, Jeff, et al. "Pseudo-data generation for the extraction of Problems, Treatments and Tests." AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science vol. 2021 (2021): 575-584.
Smith J, French E, Cramer W, Uzuner Ӧ, McInnes BT. Pseudo-data generation for the extraction of Problems, Treatments and Tests. AMIA Jt Summits Transl Sci Proc. 2021 May 17;2021:575-584. eCollection 2021. PMID: 34457173; PMCID: PMC8378614.
Copy Download .nbib Format: NLM
Showing 361 to 372 of 372 entries